Fire at Aurobindo Pharma arm Penicillin G facility, no injuries reported

Published On 2025-04-29 04:45 GMT   |   Update On 2025-04-29 04:45 GMT
Advertisement

Hyderabad: A fire broke out at Penicillin G manufacturing facility of Lyfius Pharma Private Limited, a subsidiary of Aurobindo Pharma, located in Kakinada SEZ, Thondangi (M), Kakinada District - 533449, Andhra Pradesh, India.

Aurobindo disclosed in a BSE filing that the incident occurred around 10:00 PM (IST) on April 27, 2025, in the vicinity of the coal crusher area.

The fire incident took place due to the self-ignition of coal. The company is in the process of ascertaining the exact reasons for the same.

While the incident resulted in damage to certain ancillary equipment, with no impact to the core manufacturing infrastructure.
Importantly, there were no injuries reported.

"The incident is not expected to have material impact on the operations or financials of the group. A thorough assessment of the damage is currently underway," Aurobindo stated.

As a precautionary measure and to facilitate necessary equipment replacements, operations at the plant will be temporarily paused for an estimated period of 20 to 25 days. Aurobindo also reassured stakeholders that the facility is fully insured.

"We remain committed to resuming full operations at the earliest while maintaining the highest safety and quality standards," the company added.

Read also: Aurobindo Pharma arm CuraTeQ Biologics gets positive opinion for breast cancer drug Dazublys from EMA

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma gets USFDA final, tentative nod for different strengths of deep vein thrombosis drug Rivaroxaban

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News